Journals / MN Oftalmoloji / 2020 / Cilt: 27 - Sayı: 2

The Results of Intravitreal Bevacizumab Injection for the Treatment of Macular Edema in Branch Retinal Vein Occlusion

Retina Ven Dal Tıkanıklığına Bağlı Gelişen Maküla Ödemi Tedavisinde İntravitreal Bevacizumab Enjeksiyonu Sonuçları

Pages
95–100
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Intravitreal bevacizumab was found to be safe and effective in the treatment of macular edema secondary to branch retinal vein occlusion in the short term.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To investigate the effectiveness and safety of intravitreal 1.25 mL mg/0.05 bevacizumab in patients with macular edema secondary to branch retinal vein occlusion.
📊
Key Findings & Data:Material and Method: In 33 eyes of 33 cases with macular edema secondary to branch retinal vein occlusion, intravitreal injection of bevacizumab 1.25 mg/0.05 mL was applied and examined in this retrospective clinical trial.
💡
Conclusion & Impact:Conclusion: Intravitreal bevacizumab was found to be safe and effective in the treatment of macular edema secondary to branch retinal vein occlusion in the short term.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To investigate the effectiveness and safety of intravitreal 1.25 mL mg/0.05 bevacizumab in patients with macular edema secondary to branch retinal vein occlusion. Material and Method: In 33 eyes of 33 cases with macular edema secondary to branch retinal vein occlusion, intravitreal injection of bevacizumab 1.25 mg/0.05 mL was applied and examined in this retrospective clinical trial. The average duration of branch retinal vein occlusion diagnosis was 10.84±13.99 (1-58) weeks. The study included the cases of branch retinal vein occlusion who had central foveal thickness of more than >250 μm optical coherence tomography. Results: Mean follow-up period after the first injection was 5.24±3.27 months (1-18 months). During follow-up period, 11 patients (33.3% ) underwent 1, 9 patients (27.3%) underwent 2, 6 patients (18.2%) underwent 3, 5 patients (15.1%) underwent 4 and 2 patients (6.1%) underwent 5 injections. Best corrected visual acuity was 36.3±18.1 (5-65) letters with ETDRS chart before intravitreal bevacizumab injection. Best corrected visual acuity was found 60.4±14.6(15-83), 58.4±17.9(10-90), 64.1±14.5(35-80), 60.5±14.0(30-75), 63±5.8(55-70), 57.5±12.3(35-75) letters in regular monthly follow-up period, respectively. The increase in visual acuity was statistically significant at the 1st, 2nd, 3rd, 4th, 5th and 6th months after injection according to the ETDRS letter value. Pre-and post-treatment 1st, 2nd, 3rd, 4th, 5th, 6th month’s central foveal thickness measurements were 575.7±100.6; 344.4±123.9; 403.1±144.0; 362.7±158.6; 402.4±156.6; 424.6±154.3; 445.36±206.90 μm respectively. Central macular thickness decrease was found statistically significant. Improvement of visual acuity and central macular thickness decrease was found to be statistically corraleted. No systemic or ocular complication was recorded. Conclusion: Intravitreal bevacizumab was found to be safe and effective in the treatment of macular edema secondary to branch retinal vein occlusion in the short term.

Özet

Amaç: Retina ven dal tıkanıklığına bağlı maküla ödemi nedeniyle intravitreal 1,25 mg/0,05 mL bevacizumab enjeksiyonu yapılan olgularda bevacizumab enjeksiyonunun etkinlik ve güvenilirliğini araştırmak. Gereç ve Yöntem: Bu retrospektif klinik çalışmada maküla ödemi için intravitreal 1,25 mg/0,05mL bevacizumab enjeksiyonu uygulanan, 33 retina ven dal tıkanıklığı olgusunun 33 gözü incelendi. Olguların yaş ortalaması 62,8±10,9 (43-81) yıl, 18’i (%54,5) kadın, 15’i (%45,5) erkekti. Ortalama retina ven dal tıkanıklığı tanı süresi 10,8±13,9 (1-58) hafta idi. Çalışmaya, dosyalarından başlangıç ve enjeksiyon sonrası optik koherans tomografide santral fovea kalınlığı >250 μm olan retina ven dal tıkanıklığı olguları alındı. Bulgular: Ortalama takip süresi 5,24±3,27 ay (1-18 ay) idi. Takipleri süresince 11 olguya (%33,3) 1 kez, 9 olguya (%27,3) 2 kez, 6 olguya (%18,2) 3 kez, 5 olguya (%15,1) 4 kez ve 2 olguya (%6,1) 5 kez enjeksiyon uygulandı. İntravitreal bevacizumab enjeksiyonu yapılan olguların ETDRS eşeline göre tedavi öncesi düzeltilmiş en iyi görme keskinliği 36,3±18,1 (5-65) harf idi. Yapılan düzenli aylık kontrollerde düzeltilmiş en iyi görme keskinliği ortalama değerleri 1. ayda 60,4±14,6 (15-83), 2. ayda 58,4±17,9 (10-90), 3.ayda 64,1±14,5 (35-80), 4. ayda 60,5±14,0 (30-75), 5. ayda 63±5,8 (55-70), 6. ayda ise 57,5±12,0 (35-75) harf bulundu. Enjeksiyon öncesi ETDRS harf değerine göre enjeksiyon sonrası 1., 2., 3., 4., 5. ve 6. aylarda görme keskinliğinde görülen artış istatistiksel olarak anlamlı bulundu (p<0.01). Tedavi öncesi ve tedavi sonrası 1., 2., 3., 4., 5., 6. aydaki ortalama merkezi fovea kalınlıkları ölçümleri sırasıyla 575,7±100,6; 344,4±123,9, 403,1±144,0, 362,7±158,6, 402,4±156,6, 424,6±154,3, 445,36±206,90 μm idi. Görme keskinliğindeki artış ve santral maküler kalınlıktaki azalma istatiksel olarak ilişkili bulundu. Hiçbir olguda sistemik ya da oküler komplikasyon izlenmedi. Sonuç: Retina ven dal tıkanıklığına bağlı maküla ödemi tedavisinde intravitreal bevacizumab enjeksiyonunun erken dönemde etkili ve güvenilir olduğu düşünüldü.

🔖

Cite This Article

KARADEMİR, Z., ALTAN, T. (2020). The Results of Intravitreal Bevacizumab Injection for the Treatment of Macular Edema in Branch Retinal Vein Occlusion. MN Oftalmoloji, Cilt: 27 - Sayı: 2, 95–100. https://ajindex.com/articles/295350

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Newman-Casey PA. Stem M. Talwar N. et al. Risk factors associated with developing branch retinal vein occlusion among enrollees in a United States managed care plan. Ophthalmology. 2014
  2. 48 2. Hayreh SS. Zimmerman MB. Fundus changes in branch retinal vein occlusion. Retina. 2015
  3. Farinha C. Marques JP. Almeida E. et al. Treatment of retinal vein occlusion with ranibizumab in clinical practice: longer-term results and predictive factors of functional outcome. Ophthalmic Res. 2015
  4. 55(1):10-8 4. Rehak J. Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis and treatment modalities. Curr Eye Res. 2008
  5. Jonas JB. Akkoyun I. Kamppeter B. et al. Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye. 2004
  6. Hayreh SS. Classification of central retinal vein occlusion. Ophthal mology. 1983
  7. Boyd SR. Zachary I. Chakravarthy U. et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central retinal vein occlusion. Arch Ophthalmol. 2002
  8. Funatsu H. Yamashita H. Noma H. et al. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthal - mol. 2005
  9. Hurwitz H. Fehrenbacher L. Novotny W. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004
  10. Ferrara N. Hillan KJ. Gerber HP. Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004
  11. Rosenfeld PJ. Moshfeghi AA. Puliafito CA. Optical coherens tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age related macular degeneration. Ophthalmic Surg Laser Imag. 2005
  12. Iturralde D. Spaide RF. Meyerle CB. et al. Intravitreal bevacizumab (Avastin). treatment of macular edema in central retinal vein occlusion: a short-term study. Retina. 2006
  13. Arnarsson A. Stefánsson E. Laser treatment and the mechanism of edema reduction in branch retinal vein occlusion. Invest Ophthalmol Vis Sci. 2000
  14. Branch Vein Occlusion Study Group. Argon laser scatter photocoagulation for prevention of neovascularization and hemorrhage in branch vein occlusion. Arch. Ophthalmol. 1986
  15. 104(1):34-41. 15. Cekic O. Chang S. Tseng JJ. et al. Intravitrea